EL7.AI
StocksMedium•17 November 2026•
3 min read

Nutex Health Declares First Special Dividend as a Public Company, at $2.00 a Share

Key Facts

1Nutex Health approved a special cash dividend of $2.00 a share, which it described as its first since becoming a public company.
2The dividend is payable on December 14, 2026, to shareholders of record at the close of trading on November 30, 2026.
3Net income attributable to the company was $152.9 million in the first nine months of 2026, compared with $59.0 million in the same period of 2025.
4Total revenue fell 10.9% to $644.9 million in the first nine months of 2026, from $723.6 million a year earlier.
5NUTX shares closed at $169.7 on November 16, 2026.

Nutex Health said on November 17, 2026, that its board approved a special cash dividend of $2.00 a share, which the company described as its first cash distribution since becoming a public company. The company said the payment will be made on December 14 to shareholders of record at the close of business on November 30. The decision represents a direct return of capital to shareholders, Chief Executive Tom Vo said. Vo linked the move to strong cash flow and a solid balance sheet, saying they allow the company to return capital while continuing to invest in long-term growth. NUTX shares closed at $169.7 in the November 16 session, according to EL7 data.

The announcement set two dates two weeks apart: the payment date of December 14 and the record date for eligible shareholders, at the close of trading on November 30. The company says payment of the distribution is contingent on delivery of a certificate from the chief financial officer. The board also retained the right to amend or cancel the distribution before payment. Entitlement to the amount is therefore tied to ownership of the shares on the record date, while payment remains subject to the conditions set out by the company. The announcement did not say the special distribution would be repeated.

Management's comments on returning capital extend beyond this decision, but the company framed them as an expectation to recommend dividends, not a commitment to regular payments. It said it expects to recommend future quarterly cash dividends to the independent board. The company said each subsequent dividend would require review and approval by the independent board. It gave no assurance that these distributions would continue. Vo said the company wants to balance returning capital with investment in long-term growth, citing strong cash flow and the balance sheet as he described them.

Financial results for the first nine months of 2026 provide additional context for the decision. Net income attributable to Nutex Health was about $152.9 million, and diluted earnings per share were $21.50, compared with $59.0 million and $8.87 a share in the same period of 2025. By contrast, total revenue fell 10.9% to $644.9 million, from $723.6 million a year earlier. The company attributed the revenue decline mainly to factors that increased revenue recognized in 2025. The figures show two different year-over-year trends: higher net income and earnings per share, alongside lower total revenue.

In the third quarter, net income attributable to the company was $40.2 million, and diluted earnings per share were $5.71, compared with $55.4 million and $7.76 in the third quarter of 2025. In its hospital business, total visits rose 18.1% year over year to 54,622. Visits at existing hospitals also increased 12.4%. Vo said patient volumes are growing at existing hospitals and across the network, and cash collections remained strong during the first nine months of the year. His comments point to expanding visit volumes alongside a year-over-year decline in third-quarter net income.

Nutex Health operates in physician-led health care and operational services, with an affiliated hospital network of 28 facilities in 12 states, as well as a population health management division. The company says its business is organized into 3 divisions: hospitals, population health management and real estate. The hospitals division includes models such as micro-hospitals, specialty hospitals and outpatient departments. As of September 30, 2026, cash and cash equivalents were $249.9 million, compared with $185.6 million on December 31, 2025. The company described cash flow and its balance sheet as the basis for its capital return decision, while continuing to focus on long-term growth.

Open on chart